Podoplanin: An emerging cancer biomarker and therapeutic target

Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnan, Harini, Rayes, Julie, Miyashita, Tomoyuki, Ishii, Genichiro, Retzbach, Edward P., Sheehan, Stephanie A., Takemoto, Ai, Chang, Yao‐Wen, Yoneda, Kazue, Asai, Jun, Jensen, Lasse, Chalise, Lushun, Natsume, Atsushi, Goldberg, Gary S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980289/
https://www.ncbi.nlm.nih.gov/pubmed/29575529
http://dx.doi.org/10.1111/cas.13580
Descripción
Sumario:Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR‐T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

Ejemplares similares